Author

A. Padzik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Organism:zebrafish· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

I. Paatero· 5 shared J. Ivaska· 4 shared J. Westermarck· 2 shared O. M. Andersen· 2 shared P. Taimen· 2 shared A. Aakula· 1 shared A. Carisey· 1 shared A. Erickson· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

I. Paatero

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis

M. Momeny, M. Tienhaara, D. Chakroborty, M. Sharma, R. Varjus, J. Merisaari, A. Padzik, A. Vogt, I. Paatero, K. Kurppa, K. Elenius, T. D. Laajala, J. Westermarck

This study identifies DUSP6 as a driver of HER2 inhibitor tolerance through the Neuregulin/HER3 axis by analyzing the transcriptional changes during the DTP-DTEP transition in HER2+ breast cancer cells.

bioRxiv · Jun 14, 2023 · PreprintCancer Biology

PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers

A. Aakula, A. Isomursu, C. Rupp, A. Erickson, O. Kauko, P. Shah, A. Padzik, Y. R. Pokharel, A. Kaur, S.-P. Li, L. Trottman, P. Taimen, A. Rannikko, J. Lammerding, I. Paatero, , J. Westermarck

This study identifies PME-1 as a biomarker for aggressive PTEN-deficient prostate cancers by showing its role in suppressing anoikis.

bioRxiv · Mar 17, 2022 · PreprintCancer Biology

A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance

H. Al-Akhrass, J. R. W. Conway, A. S. A. Poulsen, I. Paatero, J. Kaivola, A. Padzik, O. M. Andersen, J. Ivaska

This study identifies a feed-forward loop involving SorLA and HER3 that enhances heregulin response and neratinib resistance in breast cancer.

bioRxiv · Jun 10, 2020Cancer Biology

SORLA-driven endosomal trafficking regulates the oncogenic fitness of HER2

M. Pietila, P. Sahgal, E. Peuhu, N. Jantti, I. Paatero, O. M. Andersen, A. Padzik, M. Blomqvist, I. Saarinen, P. Bostrom, P. Taimen, J. Ivaska

This study shows SORLA regulates HER2 trafficking, affecting its oncogenic activity and response to therapy.

bioRxiv · Apr 11, 2018Cell Biology

FiloQuant reveals increased filopodia density during DCIS progression

G. Jacquemet, I. Paatero, A. Carisey, A. Padzik, J. Orange, H. Hamidi, J. Ivaska

FiloQuant quantifies filopodia density and dynamics in various cell types and microenvironments, revealing increased filopodia density during DCIS progression.

bioRxiv · Apr 6, 2017Cell Biology